Korea's 1st homegrown obesity drug likely to intensify price competition

Korea's first homegrown obesity drug, Eppe, is set to launch in the market. This could lead to increased competition among obesity treatment providers, as Eppe is a domestically developed product. The launch of Eppe may cause prices of existing obesity treatments to drop, such as Mounjaro, which has seen significant price reductions in China. This could make obesity treatments more affordable for Koreans, who have been traveling to Japan to obtain cheaper versions of these drugs.

Why it matters

Korea's first homegrown obesity drug could increase competition in the market, potentially lowering prices and affecting sales of existing drugs. This development may boost investor sentiment in Korean pharmaceutical companies.

Market impact

Transmission channels

Likely winners & losers

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to The Korea Times. For information only — not financial advice.